Sector News

With BMS weighing an OTC sale, could P&G bite again?

July 11, 2018
Life sciences

Procter & Gamble has already bought one consumer division from Big Pharma this year. But with Bristol-Myers Squibb’s European OTC unit potentially up for sale, could it go for another?

Maybe, according to Reuters’ sources. The news service listed P&G—along with Stada, Zentiva, Mylan and Recordati—as likely suitors. But a few of those companies are in flux; Stada was taken over by private equity firms Bain Capital and Cinven last September, and Sanofi recently sold off Zentiva to Advent for €1.9 billion.

Italy’s rare disease pharma Recordati just agreed to sell a controlling stake to private equity firm CVC Capital Partners for about $3.5 billion, which would theoretically give it cash to make a deal. And U.S.-based generics giant Mylan has shown plenty of appetite for buyouts in the past.

When it comes to M&A, though, Bristol-Myers and P&G have history, the Cincinnati Business Courier points out. Back in 2001, P&G shelled out $4.95 billion to snag haircare brands under the Clairol umbrella from the New Jersey drugmaker. A deal for BMS’ French OTC business, Upsa, would be smaller at up to €1.5 billion ($1.8 billion), Reuters’ sources say.

Plus P&G chief David Taylor is on a dealmaking roll, the Courier says. He’s racked up four buys in recent months, including a €3.4 billion ($4.21 billion) deal for a Merck KGaA consumer health unit that boasts more than 900 products across 44 countries.

If a deal between P&G and Bristol doesn’t pan out, though, it wouldn’t be the first time this year that P&G-Big Pharma rumors went nowhere. Shortly before Merck KGaA unveiled its P&G consumer sale, the company was reportedly eyeing a pricier Pfizer consumer unit for which the pharma giant ultimately couldn’t find a buyer.

Meanwhile, as Bristol weighs its options, it joins a slew of drugmakers bowing out—or trying to bow out—of the consumer health arena. Along with Merck KGaA, Novartis also exited the space this year, agreeing to hand over its share of its joint venture with GlaxoSmithKline in exchange for $13 billion from the British drugmaker. And two years ago, Boehringer Ingelheim traded away its own unit to Sanofi in exchange for the French pharma’s animal health business.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).